[Leish-l] RES: testing vaccinated dogs for immunopotentiation

Wed Sep 28 11:07:55 BRT 2011

Hi !

There are these papers about

These need a very critical reading to discuss

This discussion with all about the matter and these papers is very welcome!
(at least for me!)

Regards for all

Luiz Ristow

assinatura de email dr luiz

De: leish-l-bounces at lineu.icb.usp.br
[mailto:leish-l-bounces at lineu.icb.usp.br] Em nome de John David
Enviada em: segunda-feira, 26 de setembro de 2011 18:44
Para: Dr GR Rajasekariah
Cc: leish-l at lineu.icb.usp.br; Carlos Gouvea; hubert mazure;
smithyman at cellabs.com.au
Assunto: Re: [Leish-l] testing vaccinated dogs for immunopotentiation

I think that for any vaccine developed to protect dogs against VL, but which
is also meant to prevent transmission of VL to humans, the developers should
show that after the vaccinated dog has been challenged with Leishmania, it
does not transmit Leishmania to sand flies.

John R David, M.D.

Richard Pearson Strong Professor Emeritus

Department of Immunology and Infectious Diseases

Harvard School of Public Health

Professor of Medicine, Harvard Medical School

300 W. 23rd Street, Apt. 13K

New York, NY, 10011

Tel: 212 414 8646

Email: jdavid at hsph.harvard.edu

On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah wrote:

Hello EveryOne,
I am responding to the topic on European VL Dog vaccine.
It is a great challenge in devising a protective vaccine  against visceral
leishmaniasis in dogs. This point equally applies the same challenge for
human situation.
Because Th-2 response is so dominant during VL infection, modulating Th-2
into Th-1 response is a big challenge to immunologists.

Key points lies in the presentation of appropriate antigen in appropriate
dose to stimulate the  Th-1 dependent protective immune response.
I understand several vaccines are in the market and real efficacy of these
vaccines will come out once introduced to field conditions.

I just wanted to inform you that we have a suitable antibody kit  for
testing the immunopotentiation in dogs following vaccination of dogs.
Our assay is based on the released promastigote antigens.
It is a highly sensitive assay.
Currently we supply reagents for  determination of total IgG antibodies in
serum.
If any particular group is interested then we are able to provide
appropriate reagent for detection of specific IgG2 and other isotype
specific antibody detection.
Because our antibody detection ELISA is based on the exo-antigens such an
ELISA would be of exceptional type for measuring antibody response in
vaccinated animals.
Highly suitable for diagnosing dogs responded to vaccines.

Recently I came to know that some of  commercial kits were found to be not
useful for detecting seroconversion in dogs vaccinated with FML vaccine
(Leish-Immune) in Brazil.
Because we use released antigens in our kit, any such problems will overcome
if they use Canine Leish IgG CELISA (Manufacturer Cellabs Pty Ltd Brookvale
NSW Australia email sales at cellabs.com.au).
If any one is interested to know more about our antibody detection ELISA
based on exo-antigens please contact us.

This is for your kind information.

Dr GR Rajasekariah
Sydney
Australia
raj at cellabs.com.au

----- Original Message ----- From: <leish-l-request at lineu.icb.usp.br>
To: <leish-l at lineu.icb.usp.br>
Sent: Wednesday, August 10, 2011 5:18 PM
Subject: Leish-l Digest, Vol 44, Issue 3

Send Leish-l mailing list submissions to

leish-l at lineu.icb.usp.br

To subscribe or unsubscribe via the World Wide Web, visit

http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l

or, via email, send a message with subject or body 'help' to

leish-l-request at lineu.icb.usp.br

You can reach the person managing the list at

leish-l-owner at lineu.icb.usp.br

When replying, please edit your Subject line so it is more specific

than "Re: Contents of Leish-l digest..."

Today's Topics:

 1. European VL Dog Vaccine - CaniLeish?: (jeffrey shaw)

 2. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)

 3. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)

----------------------------------------------------------------------

Message: 1

Date: Tue, 9 Aug 2011 15:18:44 +0000

From: jeffrey shaw <jayusp at hotmail.com>

Subject: [Leish-l] European VL Dog Vaccine - CaniLeish?:

To: Leish-L <leish-l at lineu.icb.usp.br>

Message-ID: <COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>

Content-Type: text/plain; charset="windows-1252"

CaniLeish?:

  The European Commission granted a marketing authorisation valid throughout
the European Union, for CaniLeish to Virbac S.A. on 14/03/2011.

 This vaccine, CaniLeish?, will initially be launched in Portugal at the end
of the first half of 2011. This will be followed rapidly by launches in
other countries in the endemic area: Spain, France, Greece and Italy (not in
chronological order). This roll-out takes account of the geographical
prevalence of the disease and the time required to build vaccine production
up to full capacity. The launch in Northern European countries from where
there is a flow of summer visitors to the endemic area will be part of a
second phase.

  The basis of this vaccine are excreted proteins plus a saponin adjuvant
purified from Quil-A. Its efficacy was determined in a 2 year open field
trial.

  The vaccine is given to dogs as three injections, three weeks apart, under
the skin. The first injection can be given from six months of age, the
second injection is given three weeks later and the third three weeks from
the second one. Afterward a single ?booster? should be given every year to
maintain protection.

-------------- next part --------------

An HTML attachment was scrubbed...

URL:
<http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e/att
achment-0001.htm>

------------------------------

Message: 2

Date: Wed, 10 Aug 2011 13:07:17 +0600

From: Moazzem Hossain <directordcbd at gmail.com>

Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network

To: jeffrey shaw <jayusp at hotmail.com>, "Prof. Paul Kaye"

<paul.kaye at york.ac.uk>

Cc: "Prof. Dr. Moazzem Hossain" <profdrmoazzemhossain at gmail.com>,

Leish-L <leish-l at lineu.icb.usp.br>

Message-ID:

<CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.com>

Content-Type: text/plain; charset=windows-1252

10 Aug 2011

Dear Professor Paul Kaye,

Thank you for your email. Please find attached our supportive letter

of interest for Leishmaniasis Pathology Network.

Looking forward for your kind response.

Best regards.

-- 

*Prof. Dr. Moazzem Hossain *

Ex - Director Disease Control

Ministry of Health & Family Welfare

Government of  Bangladesh

*Mailing address*:

Founder Chairman and Project Director

Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)

Room 4 - 5 (2nd Floor), Green Super Market, Green Road

Dhaka -1205, Bangladesh.

Phone:880-2-8115646 (O )

        880-1715038551(Mobile)

Email: directordcbd at gmail.com

On 8/9/11, jeffrey shaw <jayusp at hotmail.com> wrote:

Date: Tue, 9 Aug 2011 11:58:52 +0100

From: paul.kaye at york.ac.uk

Subject: Leishmaniasis Pathology Network

   Dear all,

   Invitation to participate in a global pathology

     network for

     research and training in leishmaniasis (LeishPathNet)

   You may recall the Dormy House meeting in 2008

     and some of

     the plans we put forward?  Over

     the past

     couple years, I have also spoken more to a few of you about one

     idea that was

     formulated at Dormy, namely of setting up a digital pathology

     network. I have

     also had numerous discussions with the major equipment

     manufacturers to see if

     any of them would be supportive of helping us to develop such an

     initiative.  There have

     been two major

     develoments recently.  First,

     Carl Zeiss

     is willing to work with us to set up an integrated global digital

     pathology

     network (providing a significant financial and technical

     contribution) and

     second, the Wellcome Trust is willing to review a pre-proposal to

     fund the

     initiative through their new Biomedical Resources Grant scheme

(http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strate
gic-awards-and-initiatives/wtdv031727.htm)

     .

   I have attached an outline of the project that

     I had sent to

     the Trust for their initial views, which I think is reasonably

     self-explanatory.

      They appeared very

     enthusiastic!  The main

     question now is whether enough of

     you are still supportive? [ I will also be sending this email to

     others, but please feel free to circulate ]

   I think the

       project will be

       challenging, but success could have a real impact on the way we

       conduct

       business.  It should serve not only as a vehicle to enhance

       research in

       leishmaniasis, but the model would be equally applicable across

       a broad range

       of diseases and global challenges (with leishmaniasis setting

       the pace).

   If we wish to

       proceed, the requirements

       are that we submit a pre-proposal to the Trust by Oct 18th 2011.

       This pre-proposal is short (4 sections of 350 words) and

       requires

       letters of support from the community.

   If you are

       supportive of the idea that

       we try to take this forward (and there is plenty of scope for

       later iteration

       of the detail), I would be grateful if you could please provide

       me with a

       letter of support by September

         12th

         2011, indicating whether you would like to be a network

       partner if the bid

       is successful.  You could

       also be

       supportive but not wish to become directly involved at this

       stage, and such

       letters are equally valuable. Your letter might also stress the

       added value

       that the network could provide, its importance for research and

       training and/or

       for progressing the translational agenda.

       It would also be an opportunity to indicate whether your

       group (or

       institute, if multiple groups) would be interested in bidding to

       be one of the

       initial ?designated laboratories?.

   If there is

       sufficient support to

       proceed and if subsequently the pre-proposal is successful (we

       will know on 22nd

       Nov), then I will need a few volunteers to help finalise the

       full proposal,

       which will be due on Jan 26th 2012.

       A funding decision will be made on May 26th

       2012.

   Best wishes

       and of course I am happy to

       discuss any points further (though I will be out of the UK from

       Aug 10 ?Sept

       12)

   Paul

   --

Professor Paul Kaye, Ph.D., FRCPath.

Deputy Dean (Research), Hull York Medical School, and

Director, Centre for Immunology and Infection

Department of Biology and Hull York Medical School

University of York

Wentworth Way

York YO10 5YW

United Kingdom

Tel:  +44 (0)1904 328840

Fax:  +44 (0)1904 328844

Email: paul.kaye at york.ac.uk <mailto:paul.kaye at york.ac.uk>

Centre Administrator and PA: Elizabeth Greensted

Tel:  01904 328845

Email: liz.greensted at york.ac.uk <mailto:liz.greensted at york.ac.uk>

Centre Email: cii at york.ac.uk <mailto:cii at york.ac.uk>

Centre website: http://www.york.ac.uk/cii

Times Higher Education University of the Year 2010

Email disclaimer: http://www.york.ac.uk/docs/disclaimer/email.htm

------------------------------

Message: 3

Date: Wed, 10 Aug 2011 13:06:47 +0600

From: Moazzem Hossain <directordcbd at gmail.com>

Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network